RxDoctor Payments Data

Kiran Chintam, MD

Nephrology · Columbus, INNPI 1982930285

Payments from drug & device makers

$844in general payments, 2019–2025

Across 30 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$276
  • Otsuka America Pharmaceutical, Inc.$218
  • Abbott$118
  • Travere Therapeutics, Inc.$36
  • AstraZeneca$28
  • Bayer$27
  • plus $139 from 7 others

What the payments were for

  • Food & beverage$58769%
  • Education$25831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$844 in reported general payments places this provider in the 45th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$173,042
Medicare patients
502
Services billed
1,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol145$159,594
JardianceEmpagliflozin56$68,286
LokelmaSodium Zirconium Cyclosilicate49$37,504
KerendiaFinerenone12$12,988
VeltassaPatiromer Calcium Sorbitex13$9,569
Torsemide258$5,092
Losartan Potassium425$3,547
Sevelamer Carbonate31$2,511
Amlodipine Besylate341$2,439
Calcium Acetate22$2,305
Doxazosin Mesylate158$2,301
Lisinopril335$2,034
Hydralazine Hcl163$1,352
Tamsulosin Hcl77$1,336
Midodrine Hcl20$1,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$28$197,098194 claims
BayerKerendia$27$12,98812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 238 nephrology providers in Indiana.

Other nephrology in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →